ArticleOncoTargets and therapy2021
Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Integrative Proteomic Analysis Reveals VMG Oncolytic Virus-Induced Molecular Reprogramming in Pancreatic Ductal Adenocarcinoma.Research square · 2026Article
- Characterization of global research trends and prospects on celastrol, a principal bioactive ingredient ofPharmaceutical biology · 2025Article
- Perineural invasion in pancreatic cancer: Current biological function in R status, prognosis, and pain.Surgery open science · 2025Article
- Celastrol promotes DNA damage and apoptosis in uterine corpus endometrial carcinoma via promotion of KAT2B-mediated RBPJ acetylation and repression of MCM4 transcription.Molecular medicine (Cambridge, Mass.) · 2025Article
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- The role of celastrol in inflammation and diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma.OncoTargets and therapy · 2025Article
- Unraveling the Impact of Six Pentacyclic Triterpenes Regulating Metabolic Pathways on Lung Carcinoma Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Elucidating the role of phytocompounds fromIn silico pharmacology · 2024Article
- Celastrol suppresses human pancreatic cancer via mDiscover oncology · 2023Article
- Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-Journal of enzyme inhibition and medicinal chemistry · 2023Article
- What's old is new again: Insights into diabetic foot microbiome.World journal of diabetes · 2023Review
- Drug repositioning: doxazosin attenuates the virulence factors and biofilm formation in Gram-negative bacteria.Applied microbiology and biotechnology · 2023Article
- Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination againstBiomedicines · 2023Article
- Diminishing the Pathogenesis of the Food-Borne PathogenBiology · 2023Article
- Immune modulation and prognostic significance of MCM10 in pan-cancer: a comprehensive analysis.American journal of translational research · 2023Article
- Hiring of the Anti-Quorum Sensing Activities of Hypoglycemic Agent Linagliptin to Alleviate theMicroorganisms · 2022Article
- Controlling of Bacterial Virulence: Evaluation of Anti-Virulence Activities of Prazosin againstAntibiotics (Basel, Switzerland) · 2022Article
- RETRACTED: Characterization of the Anti-Biofilm and Anti-Quorum Sensing Activities of the β-Adrenoreceptor Antagonist Atenolol against Gram-Negative Bacterial Pathogens.International journal of molecular sciences · 2022Article
- Silencing ofMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is one of the most serious and lethal human cancers with a snowballing incidence around the world. The natural product celastrol has also been widely documented as a potent anti-inflammatory, anti-angiogenic, and anti-oxidant. PURPOSE: To elucidate the antitumor effect of celastrol on pancreatic cancer cells and its modulatory role on whole genome expression.
methodsThe antitumor activity of celastrol on a panel of pancreatic cancer cells has been evaluated by Sulforhodamine B assay. Caspase 3/7 and histone-associated DNA fragments assays were done for apoptosis measurement. Additionally, prostaglandin (PGE2) inhibition was evaluated. Moreover, a microarray gene expression profiling was carried out to detect possible key players that modulate the antitumor effects of celastrol on cells of pancreatic cancer.
resultsOur findings indicated that celastrol suppresses the cellular growth of pancreatic cancer cells, induces apoptosis, and inhibits PGE2 production. Celastrol modulated many signaling genes and its cytotoxic effect was mainly mediated via over-expression of
conclusionThe current study aims to be a starting point to generate a hypothesis on the most significant regulatory genes and for a full dissection of the celastrol possible effects on each single gene to prevent the pancreatic cancer growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.